Welcome to our dedicated page for enGene Holdings SEC filings (Ticker: ENGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for enGene Holdings Inc. (NASDAQ: ENGN), a British Columbia–incorporated, clinical-stage biotechnology company developing non-viral genetic medicines. Through these filings, investors can review how enGene reports clinical, regulatory, financial, and governance developments related to its lead program, detalimogene voraplasmid, and its broader corporate activities.
enGene’s current reports on Form 8-K provide detail on material events such as updated preliminary efficacy and safety data from the Phase 2 LEGEND trial in high-risk non-muscle invasive bladder cancer (NMIBC), changes to trial endpoints following discussions with the U.S. Food and Drug Administration, and enrollment status across LEGEND cohorts. Other 8-K filings describe executive and board appointments, amendments to executive employment agreements, and inducement equity awards granted under NASDAQ Listing Rule 5635(c)(4).
Filings also confirm that enGene’s common shares trade on The Nasdaq Stock Market LLC under the symbol ENGN, with warrants listed under ENGNW, and identify the company as an emerging growth company. Liquidity and capital structure information, including cash, cash equivalents and marketable securities balances and details of public offerings of common shares and pre-funded warrants, appear in financial disclosures and referenced exhibits.
On Stock Titan, users can access these SEC documents alongside AI-powered summaries that explain key points in clear language. Real-time updates from EDGAR surface new 8-Ks and other filings as they are submitted, while AI highlights sections related to clinical trial results, regulatory designations such as RMAT and Fast Track, manufacturing readiness programs like the FDA’s CDRP, and board or management changes. Form 4 insider transaction data, when filed, and periodic reports such as 10-K and 10-Q can be reviewed with AI-generated insights to help readers quickly understand complex regulatory and financial information.
enGene Holdings Inc. Chief Medical Officer Hussein Sweiti was granted a non-qualified stock option to purchase 600,000 common shares at an exercise price of $6.83 per share, with an expiration date of 09/30/2035. The grant was awarded on 09/30/2025 as an inducement award outside the company019s 2023 Incentive Equity Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The option vests 25% on 09/29/2026 (the first anniversary of employment) and the remainder vests monthly over the next three years, subject to continued service. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person and filed on 10/01/2025.
enGene Holdings Inc. filed a current report noting that it issued a press release on September 30, 2025 announcing the appointment of Dr. Hussein Sweiti as Chief Medical Officer. The press release is furnished, not filed, as Exhibit 99.1 and is not automatically incorporated into other securities filings.